一年肝脏硬度变化可预测MASLD患者长期肝脏结局
这项多中心队列研究纳入LSM≥8 kPa的MASLD患者,评估1年内LSM、CAP、ALT和FIB-4变化对肝脏结局的影响。结果显示仅1年LSM变化独立关联肝脏相关事件和肝功能失代偿风险,而CAP、ALT和FIB-4变化无此关联。
要点
- 1年LSM变化独立预测LSM≥8 kPa MASLD患者的肝脏相关事件。
- 1年LSM变化独立预测肝功能失代偿,CAP、ALT、FIB-4变化无关联。
- LSM、CAP、ALT或FIB-4的1年变化与HCC风险均无独立关联。
核心结论
- 在LSM≥8或≥10 kPa的MASLD患者中,1年LSM下降百分比与较低的肝脏相关事件和肝功能失代偿风险独立相关。
研究设计与样本
- 多中心队列研究,纳入LSM≥8 kPa的MASLD患者1744例和LSM≥10 kPa患者989例,进行前瞻性随访。
主要发现
- LSM≥8 kPa组中39例发生肝脏相关事件(26例肝功能失代偿,22例HCC),LSM≥10 kPa组中35例发生(25例肝功能失代偿,19例HCC)。
- 在LSM≥8 kPa患者中,1年LSM变化与肝脏相关事件独立相关(csHR 1.007,95%CI 1.001-1.014)。
- 1年LSM变化独立预测肝功能失代偿(csHR 1.009,95%CI 1.000-1.018),而CAP、ALT或FIB-4的1年变化无关联。
- 1年LSM、CAP、ALT或FIB-4变化与HCC风险均无独立关联。
- 上述发现在LSM≥10 kPa患者及2型糖尿病高危患者中得到验证。
临床怎么用
- 对LSM≥8 kPa的MASLD患者,可监测1年LSM变化以评估肝脏相关事件和肝功能失代偿风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The availability of new drugs for the treatment of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) underlines the need of early predictors of response to such therapies. This study evaluated the impact of 1-year changes in liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE), controlled attenuation parameters (CAP), and serum alanine aminotransferase (ALT) on liver outcomes in patients with MASLD. METHODS: A large multicenter cohort of MASLD patients with LSM ≥8 kPa and prospective follow-up was enrolled. Liver-related events (LREs), including hepatocellular carcinoma (HCC) and liver decompensation (LD), were evaluated during follow-up. LSM, CAP, ALT, and Fibrosis-4 Index (FIB-4) were assessed at baseline and at 1-year follow-up. Cause-specific Cox regression analyses were performed to correlate 1-year variation in LSM, CAP, ALT, and FIB-4 with the risk of developing LRE, LD, and HCC, in terms of cause-specific hazard ratios (csHRs). RESULTS: We included 1744 patients with LSM ≥8 kPa (median age, 55 years; 52.1% male; 58.3% obese; 55.8% with diabetes) and 989 with LSM ≥10 kPa (median age, 56 years; 50.2% male; 54.7% obese; 51% with diabetes), followed for a median of 28.2 and 32 months, respectively. LREs occurred in 39 patients with LSM ≥8 kPa (26 LD, 22 HCC) and in 35 with LSM ≥10 kPa (25 LD, 19 HCC). A 1-year variation in LSM, but not in CAP, ALT, or FIB-4, was independently associated with LRE in patients with MASLD and LSM ≥8 kPa (csHR, 1.007; 95% confidence interval [CI], 1.001-1.014). Likewise, 1-year LSM variation (csHR, 1.009; 95% CI, 1.000-1.018) independently predicted LD in this population, whereas no 1-year changes in CAP, ALT, or FIB-4 were associated with LD risk. No independent associations were observed between 1-year changes in LSM, CAP, ALT, or FIB-4 and the risk of HCC. All findings were confirmed in patients with LSM ≥10 kPa and in those at high risk of progression with type 2 diabetes. CONCLUSIONS: In patients with MASLD and LSM ≥8 or ≥10 kPa, the % LSM reduction at 1 year was independently associated with lower risk of LRE and LD.
引用
- Pennisi G, Infantino G, Di Maria G, et al. One-Year Changes in Liver Stiffness Measurement, but Not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-Term Liver Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Clin Gastroenterol Hepatol. 2026. PMID: 41621770. doi:10.1016/j.cgh.2026.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。